Serum anti-Müllerian hormone and inhibin B as potential markers

for progressive central precocious puberty in girls

Ting Chen^a, Haiying Wu^a, Rongrong Xie^a, Fengyun Wang^a, Xiuli Chen^a, Hui Sun^a, and Linqi Chen a,*

^aDepartment of Endocrinology, Children's Hospital of Soochow University, Suzhou, Jiangsu 215000, China

OBJECTIVES

To investigate the potential of serum anti-Müllerian hormone (AMH) and inhibin B (INHB) levels as markers for pubertal progression rate in girls with central precocious puberty (CPP).




Figure 1. Serum AMH (A) and INHB (B) levels in girls.




Figure 2. ROC cureves for the analysis of AMH and INHB (A), and basal and peak LH (B).

	P-CPP	SP-CPP	PT	Control
Age (yr)	6.50 (5.00-	6.75 (5.33-	6.75 (5.25-	6.67 (5.42-
	8.00)	8.00)	8.00)	7.92)
BMI (kg/m²)	15.60 (13.89-	15.79 (14.16-	15.35 (13.95-	14.75 (13.97-
	16.48)	16.25)	16.25)	16.31)
Pana aga (vr)	8.6 (7.3-	8.9 (7.8-	7.8 (6.3-9.6)	6.3 (5.0-8.0)
Bone age (yr)	11.2) *&	11.1) *&	*	0.5 (5.0-8.0)
Uterine	23 (11_31)*&	24 (20_27) *&	19 (13-26)*	17 (14-20)
length (mm)	23 (14-34)	24 (20-27)	19 (13-20)	17 (14-20)
Uterine	2.38 (0.64-	2.56 (1.47-	1.17 (0.59-	0.65 (0.26-
volume (ml)	5.48) *&	3.56) *&	2.49)*	1.81)
Ovarian	2.21 (1.03-	2.23 (1.12-	1.46 (0.65-	0.82 (0.31-
volume (ml)	4.92) *&	3.63) *&	3.61)*	2.14)

Table 1. Clinical and ultrasound characteristics of the four groups. Data are expressed as median (range). * p < 0.05: significantly different compared to subjects with controls. & p < 0.05: significantly different compared to subjects with PT group.

METHODS

A total of 128 girls were enrolled, including 65 girls with premature thelarche (PT) and 63 girls with CPP, grouped based on the results of Gonadotropin-releasing hormone (GnRH) stimulation tests. Serum AMH and INHB levels were assessed in all enrolled girls. Girls with CPP underwent a six-month follow-up, and were further divided into two subgroups: progressive CPP (P-CPP) group (n=50) and slowly progressive CPP (SP-CPP) group (n=13).

RESULTS

Our data showed that AMH and INHB offer the potential to act as markers that distinguish SP-CPP from P-CPP. Compared with SP-CPP group, girls with P-CPP showed lower AMH level (2.79 (1.04-6.16) ng/ml vs 4.82 (1.94-11.15) ng/ml, p=0.0047) and higher INHB level (56.94 (16.54-123.60) pg/ml vs 27.61(19.46-67.48) pg/ml, p=0.1628). Based on the receiver operating characteristics (ROC) analysis, the area under the curve (AUC) was 0.88 for the combination of AMH and INHB, with 93% sensitivity and 71.5% specificity.

	P-CPP	SP-CPP	PT	Control
BasalE2	43.8 (27.6-	41.9 (22.5-	13.2 (<11.8-	<11.8
(pmol/L)	173.2) *&	94.4) *&	35.4)	(<11.8-15.6)
Basal LH	0.31 (0.11-	0.25 (0.12-	< 0.07	< 0.07
(IU/L)	1.92) *&	$0.41)^{*}$	(<0.07-0.26)	(<0.07-0.09)
Basal FSH	2.66 (0.73-	2.32 (0.89-	2.37 (<0.1-	0.85 (<0.1-
(IU/L)	7.35)*	5.46)*	5.4)	2.13)
Peak LH	5.93 (5.01-	6.50 (5.08-	2.36 (1.06-	NA
(IU/L)	22.06) &	10.20) &	4.80)	
Peak FSH	13.04(6.13-	15.46(9.48-	17.16(7.06-	NA
(IU/L)	17.92) &	20.38) &	28.50)	
LH:FSH	0.51(0.32-	0.38(0.25-	0.14(0.04-	NA
Ratio	1.57) &	0.65) &	0.37)	

Table 2. Serum hormone levels of the four groups. Data are expressed as median (range). * p < 0.05: significantly different compared to subjects with controls. & p < 0.05: significantly different compared to subjects with PT group.

CONCLUSIONS

Our results suggest that serum AMH and INHB levels provide a reliable method in differentiating SP-CPP from P-CPP.

References

- Mogensen SS, Aksglaede L, Mouritsen A, et al: Diagnostic work-up of 449 consecutive girls who were referred to be evaluated for precocious puberty. J Clin Endocrinol Metab 2011; 96: 1393-1401.
- Palmert MR, Malin HV, Boepple PA: Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999; 84: 415-423.
- De FG, Rendina D, Nazzaro A, et al: Baseline inhibin B levels for diagnosis of central precocious puberty in girls. Horm Res Paediatr 2013; 80: 207-212.
- Sehested A, Andersson A, Muller J, et al: Serum Inhibin A and Inhibin B in Central Precocious Puberty before and during Treatment with GnRH Agonists. Horm Res 2000; 54: 84-91.



Ting Chen

Neuroendocrinology DOI: 10.3252/pso.eu.55ESPE.2016







